Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects aged ≥ 40 years at Screening visit.~2. Adequate contraception:~3. Diagnosis of fixed airflow obstruction with elevated eosinophils~4. Subjects symptomatic at Visit 1 (CAT ≥10) despite currently receiving treatment with either LAMA or LABA monotherapy or LAMA + LABA as a combination inhaler or separate inhalers.~5. Documented history of ≥ 1 moderate or severe respiratory disease exacerbations (requiring treatment with systemic corticosteroids and/or antibiotics and/or hospitalisation) in the previous year.~6. Willing and able to replace current therapy for obstructive lung disease with study medication.~7. Able to demonstrate correct use of a BAI, Breezehaler and pMDI.~Exclusion Criteria:~1. Respiratory disease exacerbation between 4 weeks prior to screening and Visit 3 (Randomisation).~2. Previous treatment with ICS.~3. Documented evidence of α1-antitrypsin deficiency.~4. Other active respiratory disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease, cystic fibrosis, bronchiolitis obliterans.~5. Use of long-term oxygen therapy (LTOT) at least 12 hours daily or mechanical ventilation.~6. Chest X-ray or CT scans performed prior to screening which reveal evidence of clinically significant abnormalities reflective of active disease not believed to be due to COPD~7. Evidence of uncontrolled cardiovascular disease.~8. Evidence of clinically significant renal, hepatic, gastrointestinal, or psychiatric disease.~9. Current malignancy or a previous history of cancer which has been in remission for \< 5 years (basal cell or squamous cell carcinoma of the skin which has been resected is not excluded).~10. Clinically significant sleep apnoea requiring use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.~11. Participation in the acute phase of a pulmonary rehabilitation programme within 4 weeks prior to screening or during the study.~12. Known or suspected history of drug or alcohol abuse in the last 2 years.~13. Requiring treatment with any of the prohibited concomitant medications.~14. Known or suspected hypersensitivity or contraindication to any of the study drugs or excipients.~15. Received an investigational drug within 30 days of the Screening.~16. Received a systemic corticosteroid within 30 days of the Screening visit.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluticasone/formoterol BAI (Type: EXPERIMENTAL): To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
- Ultibro Breezhaler (Type: ACTIVE_COMPARATOR): Ultibro Breezhaler 85/43 µg (1 puff o.d.)

Based on this trial design, predict the completion outcome and termination type (if applicable).